Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05661461
Other study ID # HEP-001
Secondary ID
Status Recruiting
Phase Phase 1
First received
Last updated
Start date November 23, 2022
Est. completion date April 1, 2025

Study information

Verified date December 2023
Source Aadi Bioscience, Inc.
Contact Aadi Medical Information
Phone 1-888-246-2234
Email MedInfo@aadibio.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a phase 1, multi-center, open-label, dose-escalation study of nab-sirolimus in adult patients with locally advanced or metastatic solid tumors and moderate hepatic impairment or normal hepatic function.


Description:

This is a phase 1, multi-center, open-label, dose-escalation study of nab-sirolimus in adult patients with locally advanced or metastatic solid tumors and moderate hepatic impairment or normal hepatic function. Eligible patients will receive nab-sirolimus by intravenous (IV) infusion over 30 minutes (+10 min) on Days 1 and 8.


Recruitment information / eligibility

Status Recruiting
Enrollment 28
Est. completion date April 1, 2025
Est. primary completion date April 1, 2025
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - For All Patients 1. Willing and able to provide informed consent and comply with protocol requirements for the duration of the study. 2. Male or female patients at least 18 years of age at the time of signing the informed consent form. 3. Histologically confirmed locally advanced or metastatic solid tumors that is measurable or non-measurable. 4. Eastern Cooperative Oncology Group (ECOG) performance status score of 0, 1, or 2. 5. Adequate hematologic counts: - Absolute neutrophil count (ANC) =1.0 × 109 /L (growth factor support allowed) - Platelet count =75,000/mm 3 (75 × 10 9 /L) (transfusion and/or growth factor support allowed) - Hemoglobin =8.0 g/dL (transfusion and/or growth factor support allowed) 6. Creatinine clearance =30 mL/min as assessed by the Cockcroft-Gault equation: Creatinine Clearance =30 = (140 - age) × (weight[kg] / (72 x SCr[mL/min]_ x 0.85, if female 7. Fasting serum triglyceride must be =300 mg/dL; fasting serum cholesterol must be =350 mg/dL. 8. Male or non-pregnant and non-breastfeeding female: - Females of child-bearing potential must agree to use highly effective contraception or abstinence without interruption from 28 days prior to first dose throughout 3 months after last dose and have a negative pregnancy test (urine or serum) result at screening and after the end of study treatment. A second form of birth control is required even if she has had a tubal ligation. - Male patients must practice abstinence or agree to use a condom during sexual contact with a pregnant female or a female of childbearing potential while participating in the study and throughout 3 months after last dose. A second form of birth control is required even if he has undergone a successful vasectomy. 9. Minimum of 4 weeks since major surgery, completion of radiation, or completion of all prior systemic anticancer therapy, or at least 5 half-lives if the prior therapy is a single agent small-molecule therapeutic, and in either case adequately recovered from the acute toxicities of any prior therapy (including neuropathy) to Grade =1. For Patients with Normal Hepatic Function 10. Normal hepatic function (total bilirubin = upper limit of normal [ULN] and aspartate aminotransferase [AST] =ULN). For Patients with Moderate Hepatic Impairment 11. Moderate hepatic impairment (total bilirubin 1.5-3.0 × ULN and any level of AST) Exclusion Criteria: 1. Received prior treatment with an mTOR inhibitor within 4 weeks prior to first dose. 2. Patients who have any severe and/or uncontrolled medical or psychiatric conditions or other conditions that could affect their participation including: 1. Patients with meningeal carcinomatosis, leptomeningeal carcinomatosis, spinal cord compression, untreated brain metastases or symptomatic or unstable brain metastases. Note: Patients with stable brain metastases (defined as asymptomatic or no requirement for high-dose [defined as dexamethasone 10 mg daily or higher] or increasing dose of systemic corticosteroids) and without imminent need of radiation therapy are eligible. If applicable, patients must have completed brain radiation therapy and recovered adequately from any associated toxicity and/or complications prior to eligibility assessment. For patients who have received prior radiation therapy, post-treatment magnetic resonance imaging (MRI) scan should show no increase in brain lesion size/volume. 2. Unstable angina pectoris, symptomatic congestive heart failure (New York Heart Association, NYHA class III or IV), myocardial infarction =6 months prior to first study treatment, serious uncontrolled cardiac arrhythmia or any other clinically significant cardiac disease. 3. Pre-existing severely impaired lung function. If a patient has a pre-existing pulmonary condition, eligible patients should have a spirometry and diffusing capacity for carbon monoxide (DLCO) that is >50% of the normal predicted value and/or O2 saturation that is >88% at rest on room air (Note: spirometry and pulmonary function tests [PFTs] not required to be performed unless clinically indicated). 4. Nonmalignant medical illnesses that are uncontrolled or whose control may be jeopardized by the treatment with the study therapy. Note, controlled non melanoma skin cancers, carcinoma in situ of the cervix, resected incidental prostate cancer, or other adequately treated carcinoma-in-situ may be eligible, after documented discussion with the Medical Monitor. 5. Uncontrolled hypertension (systolic blood pressure =160 mmHg and/or diastolic blood pressure =100 mmHg). 6. Patients with history of interstitial lung disease and/or pneumonitis, or pulmonary hypertension. 7. Individuals with known human immunodeficiency virus (HIV) infection are excluded from this study as combination antiretroviral therapy could potentially result in significant pharmacokinetic interactions. In addition, these individuals are at increased risk of serious infections due to the immunosuppressive effects of mTOR inhibition. 8. Active Hepatitis B or Hepatitis C, with detectable viral load. Note: A detailed assessment of Hepatitis B/C medical history and risk factors must be done at screening for all patients. 3. Have active severe (Grade =3) infection requiring intravenous (IV) antibiotics (contact medical monitor for clarification). 4. High-dose systemic corticosteroids (>10 mg of prednisone or its equivalent) are not permitted within 2 weeks of first dose. However, inhaled, intranasal, intra articular, and topical steroids are allowed. 5. Have a history of Gilbert's disease. 6. Any condition that in the opinion of the Investigator would place the patient at an unacceptable risk or cause the patient to be unlikely to fully participate or comply with study procedures. For Patients with Moderate Hepatic Impairment 7. Had a clinical exacerbation of liver disease within the 2-week period prior to first dose (ie, abdominal pain, nausea, vomiting, anorexia, or fever). 8. Have clinically demonstrable, tense ascites. 9. Had evidence of acute viral hepatitis within 1 month prior to first dose. 10. Have evidence of hepatorenal syndrome. 11. Have a transjugular intrahepatic portosystemic shunt. 12. Have active stage 3 or 4 encephalopathy.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
nab-sirolimus
This is a phase 1, multi-center, open-label, dose-escalation study of nab-sirolimus in adult patients with locally advanced or metastatic solid tumors and moderate hepatic impairment or normal hepatic function.

Locations

Country Name City State
United States South Texas Accelerated Research Therapeutics, LLC San Antonio Texas
United States START Mountain Region West Valley City Utah

Sponsors (1)

Lead Sponsor Collaborator
Aadi Bioscience, Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary MTD for patients with moderate hepatic impairment Through Day 22
Primary Maximum concentration (Cmax) Time 0
Primary Area under the serum concentration-time curve Time 0 to time of the last quantifiable concentration (AUC 0-last)
Primary Area under the serum concentration-time curve Time 0 to 168 hours (AUC 0-168)
Secondary Area under the serum concentration-time curve Time 0 extrapolated to infinity (AUC0-inf)
Secondary Time to maximum observed serum concentration (T max) Time 0 to 168 hours (AUC 0-168)
Secondary Clearance (CL) Time 0 to 168 hours (AUC 0-168)
Secondary Total volume of distribution during the terminal phase (V z ) Time 0 to 168 hours (AUC 0-168)
Secondary Steady-state volume of distribution (V ss) Time 0 to 168 hours (AUC 0-168)
Secondary Terminal elimination rate constant (?z ) Time 0 to 168 hours (AUC 0-168)
Secondary Terminal elimination half-life (t½ ) Time 0 to 168 hours (AUC 0-168)
Secondary Accumulation ratio based on Cmax Time 0 to 168 hours (AUC 0-168)
Secondary Accumulation ratio based on AUC0-168 Time 0 to 168 hours (AUC 0-168)
Secondary Percent area under the serum concentration-time curve extrapolated (%AUCextrap ) Time 0 to 168 hours (AUC 0-168)
See also
  Status Clinical Trial Phase
Recruiting NCT06223308 - A Study Evaluating the Safety and Efficacy of HB0028 in Subjects With Advanced Solid Tumors Phase 1/Phase 2
Not yet recruiting NCT05515185 - B7-H3 Targeting CAR-T Cells Therapy for B7-H3 Positive Solid Tumors Early Phase 1
Completed NCT05508100 - Dose Confirmation and Dose Expansion Phase 1 Study of IO-108 and IO-108 + Anti-PD-1 in Solid Tumors Phase 1
Recruiting NCT05094804 - A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents Phase 1/Phase 2
Completed NCT02836600 - A Study of LY3039478 in Japanese Participants With Advanced Solid Tumors Phase 1
Recruiting NCT04890613 - Study of CX-5461 in Patients With Solid Tumours and BRCA1/2, PALB2 or Homologous Recombination Deficiency (HRD) Mutation Phase 1
Recruiting NCT04390737 - Evaluate the Safety and Clinical Activity of HH2853 Phase 1/Phase 2
Recruiting NCT05981703 - A Study Investigating BGB-26808 Alone or in Combination With Tislelizumab in Participants With Advanced Solid Tumors Phase 1
Recruiting NCT06007482 - A Study of ES009 in Subjects With Locally Advanced or Metastatic Solid Tumors Phase 1
Completed NCT04108676 - Effect of Omeprazole on PK of Fluzoparib in Healthy Male Subjects Phase 1
Recruiting NCT05798611 - Study of ART0380 in Patients With Biologically Selected Solid Tumors Phase 2
Recruiting NCT05076396 - PM14 Administered Intravenously to Patients With Advanced Solid Tumors Phase 1
Recruiting NCT06008366 - A Phase 1/2 Study of 7MW3711 in Advanced Solid Tumors Phase 1/Phase 2
Recruiting NCT06054932 - Safety, Tolerability, and Immunogenicity of LK101 Alone in Participants With Incurable Solid Tumors Phase 1
Recruiting NCT04825392 - A Phase Ib Study of HX008 in Patients With Advanced Solid Tumors Phase 1
Active, not recruiting NCT04242199 - Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099280 in Participants With Advanced Solid Tumors Phase 1
Not yet recruiting NCT06365918 - Study of VG2025 Delivered Intraperitoneally in Patients With Advanced Solid Tumors With Carcinomatosis Phase 1
Recruiting NCT05461287 - Safety, Tolerability and Pharmacokinetics Study of QLS31904 in Patients With Advanced Solid Tumors Phase 1
Recruiting NCT05569057 - A Phase I Trial of SIM1811-03 in Subjects With Advanced Solid Tumors and Cutaneous T-cell Lymphoma Phase 1
Recruiting NCT05443126 - A Study of EP0031 in Patients With Advanced RET-altered Malignancies Phase 1/Phase 2